BrainsWay Receives FDA Clearance for Accelerated Deep TMS Protocol for Non-Invasive Treatment of Major Depressive Disorder (MDD)

Stock Information for BrainsWay Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About BrainsWay Ltd.

BrainsWay to Host Virtual Analyst & Investor Day to Discuss the Company's Growth Strategy and Deep TMS(TM) Treatment December 1, 2025
BrainsWay Launches First Clinical Trial of Deep TMS 360(TM) System for Alcohol Use Disorder
BrainsWay Receives FDA Clearance of Deep TMS(TM) as Adjunct Therapy for Major Depressive Disorder (MDD) in Adolescents Aged 15 to 21
BrainsWay Reports Third Quarter 2025 Financial Results and Operational Highlights
BrainsWay Reports National Institutes of Health Grant to Leading U.S. Research Team Investigating Accelerated Deep TMS for Treatment of Alcohol Use Disorder
BrainsWay to Report Third Quarter 2025 Financial Results on November 11, 2025
BrainsWay Announces Additional Minority-Stake Investments in Leading U.S. Mental Health Providers
Neurolief Prepares for Launch of its Proliv(TM)Rx System for Major Depressive Disorder with Strategic Investment from BrainsWay

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.